Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis
Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis

March 19, 2019

A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients.

The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, all of whom were 16 years old or under, 67 percent received MMF and 33% received IVCYC.

This was the largest study investigating treatments for lupus nephritis in children, and showed that treatment with MMF is comparable to standard treatment with IVCYC.

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates